Abstract: Described are compositions and methods relating to variant filamentous fungi having altered growth characteristics. Such variants are well-suited for growth in submerged cultures, e.g., for the large-scale production of enzymes and other proteins for commercial applications.

Abstract: The present disclosure describes methods for concentrating microorganisms with concentration agents in a sampling device and the sampling device described herein. More specifically, methods for concentrating microorganisms from large volume samples with concentration agents in a sampling device can provide for rapid, low cost, simple (involving no complex equipment or procedures), and/or effective processes under a variety of conditions.

Abstract: The invention provides peptide compositions and mixtures useful for the detection of antibodies that bind to Ehrlichia antigens. The peptide compositions and mixtures comprise polypeptide sequences based on an immunogenic fragment of the Ehrlichia Outer Membrane Protein 1 (OMP-1) protein. The invention also provides devices, methods, and kits comprising such peptide compositions and mixtures useful for the detection of antibodies that bind to Ehrlichia antigens and the diagnosis of monocytic and/or granulocytic ehrlichiosis.

Abstract: Methods for obtaining highly pure native, recombinant or modified BAD-1 protein include the steps of culturing a population of microbes expressing BAD-1 protein in a culture medium, collecting the population of microbes from the culture medium, obtaining a BAD-1 protein-containing solution, and purifying the BAD-1 protein from the solution by combining the BAD-1 protein-containing solution with a nickel-chelating resin, washing the nickel-chelating resin to remove unbound matter, and eluting the BAD-1 protein from the nickel-chelating resin. Highly pure native BAD-1 protein may be used in diagnostic kits for detecting Blastomyces dermatitidis infections in animals.

Abstract: The invention provides peptide compositions and mixtures useful for the detection of antibodies that bind to Ehrlichia antigens. The peptide compositions and mixtures comprise polypeptide sequences based on an immunogenic fragment of the Ehrlichia Outer Membrane Protein 1 (OMP-1) protein. The invention also provides devices, methods, and kits comprising such peptide compositions and mixtures useful for the detection of antibodies that bind to Ehrlichia antigens and the diagnosis of monocytic and/or granulocytic ehrlichiosis.

Abstract: The present invention provides a modified biotin-binding protein comprising an amino acid sequence represented by SEQ ID NO: 2 or its modified sequence and having a biotin-binding activity and replacement selected from the group consisting of: 1) replacement of the 36th serine residue of SEQ ID NO: 2 with an amino acid residue that does not form a hydrogen bond; 2) replacement of the 80th tryptophan residue of SEQ ID NO: 2 with a hydrophilic amino acid residue; 3) replacement of the 116th aspartic acid residue of SEQ ID NO: 2 with an amino acid residue that does not form a hydrogen bond; 4) replacement of the 46th proline residue of SEQ ID NO: 2 with a threonine, serine, or tyrosine residue and replacement of the 78th threonine residue of SEQ ID NO: 2 with an amino acid residue that does not form a hydrogen bond; 5) replacement of the 46th proline residue of SEQ ID NO: 2 with a threonine, serine, or tyrosine residue and replacement of the 116th aspartic acid residue of SEQ ID NO: 2 with an amino acid that

Abstract: The invention relates to fusion proteins comprising an amino acid sequence of a fragment H corresponding to a fragment of a calcium binding protein excreted-secreted by adult worms of Fasciola hepatica, followed by an amino acid sequence corresponding to a unrelated protein or fragment of protein, pharmaceutical compositions, vaccines and adjuvants containing the immunogen, to a process for their preparation, another process for the production of antibodies and their use. The present invention relates to the preparation of immunogens by the addition of a peptide sequence. Thus the present invention is useful for producing an immune response, with increases in specific antibody titers in serum against proteins or other antigens and can be applied in particular for the production of specific polyclonal antibodies, immunotherapy and immunoprophylaxis.

Abstract: A label-free biochemical assay, in which label-free interrogation of a target-receptor layer is performed while the target-receptor layer is subjected to a relatively strong flow of an analyte-containing fluid. The volumetric flow rate for the assay is selected based on calibration data corresponding to the target substance, which advantageously results in fewer and/or smaller false-positive signals corresponding to non-target substances compared to those produced with the fluid being stationary. In various embodiments, the label-free interrogation method can be electro-mechanical and/or optical.

Abstract: The present invention provides an isolated lactic acid bacterium, Lactobacillus plantarum subsp. plantarum K37 strain, deposited in DSME-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GmbH under Accession No. DSM 27445. The present invention further provides a pharmaceutical composition comprising the isolated lactic acid bacterium (Lactobacillus plantarum subsp. plantarum K37). Moreover, the present invention provides a method for preventing or treating a disorder in a subject, comprising a step of administering an effective amount of the isolated lactic acid bacterium (Lactobacillus plantarum subsp. plantarum K37) to the subject.

Abstract: The disclosure relates to uses of a purified or isolated lectin to kill bacteria, viruses, and other pathogens. In certain embodiments, the disclosure relates to method of treating or preventing an infection comprising administering a purified or isolated galectin to a subject in need thereof. In certain embodiments, the subject is at risk of, exhibiting symptoms of, or diagnosed with a pathogenic infection.

Abstract: The present invention includes a composition including as one component a slurry matrix that is a liquid at room temperature and a gel at physiological pH, physiological salt concentrations and/or physiological temperatures and as a second component one or more antigens. Also include are methods of inducing an immune response in a subject and vaccinating a subject by administering such compositions.

Abstract: The present invention encompasses methods and compositions for detecting pathogenic bacteria. Additionally, the present invention encompasses methods and compositions for catalyzing the dismutation of superoxide radicals. Further, the present invention encompasses methods for determining the antibiotic susceptibility of pathogenic bacteria.

Abstract: The invention relates to compositions comprising immunoglobulin for use in the treatment of mucositis by topical application. In particular, the invention relates to compositions comprising J chain-containing IgA and secretory component for the treatment of mucositis.

Abstract: The present invention provides a monoclonal antibody that specifically binds to acid-fast bacillary lipoarabinomannan, particularly tubercle bacillary lipoarabinomannan, the antibody being set forth below: (A) a monoclonal antibody comprising a heavy chain variable region and a light chain variable region joined via a linker, the heavy chain variable region comprising heavy chains CDR1 to CDR3 shown in (a) to (c) below, and the light chain variable region comprising light chains CDR1 to CDR3 shown in (d) to (f) below: (a) heavy chain CDR1 consisting of the amino acid sequence set forth in SEQ ID NO: 1, (b) heavy chain CDR1 consisting of the amino acid sequence set forth in SEQ ID NO: 2, (c) heavy chain CDR1 consisting of the amino acid sequence set forth in SEQ ID NO: 3, (d) light chain CDR1 consisting of the amino acid sequence set forth in SEQ ID NO: 4, (e) light chain CDR1 consisting of the amino acid sequence set forth in SEQ ID NO: 5, and (f) light chain CDR1 consisting of the amino acid sequence set fo

Abstract: The present invention relates to a novel phage, which is newly isolated and identified, a composition for inhibiting growth of bacteria or killing thereof comprising the same as an active ingredient, and the present invention can be diversely used as a composition for preventing or treating bacterial infectious diseases, a composition for treating ballast water, an antibiotic, an antiseptic, a feed additive and the like.

Abstract: The invention relates to antigens, associated with sterile immunity, and methods of their use, in an immunogenic formulation to confer an immune response against Plasmodium falciparum. The inventive antigens were identified by their association with sterile immunity against malaria.

Abstract: The present invention relates to novel tacrolimus analogs, a composition for the prevention or treatment of neurological diseases or immune hypersensitivity disorders comprising the same, a method for preventing or treating neurological diseases or immune hypersensitivity disorders comprising administering the analogs to a subject, a method for preparing the analogs using an isolated modified Streptomyces sp. strain wherein the activity of one or more enzymes selected from the group consisting of TcsA, TcsB, TcsC and TcsD is reduced; and the isolated modified Streptomyces sp. strain for prepare the analogs.

Abstract: Compositions and methods for the treatment or prevention of Clostridium difficile infection in a subject are provided. The compositions comprise antibodies to Clostridium difficile toxin A. The methods provide for administering the antibodies to a subject in an amount effective to reduce or eliminate or prevent relapse from Clostridium difficile bacterial infection.

Abstract: In embodiments there are disclosed culture media, compositions for supplementing culture media, and methods for culturing biological samples. In embodiments the methods are methods for detecting bacteria and in embodiments the bacteria include Salmonella spp and in embodiments include E. coli spp. In embodiments the media and compositions comprise an alkanolamine and a cobalamin compound.

Abstract: A biological growth inhibition factor assay method includes: a first step of mixing a photosynthetic sample, with an aqueous solution sample to prepare a test measurement solution, letting the test measurement solution stand, and then after illuminating light onto the test measurement solution for a predetermined illumination time, measuring the light amount of the delayed fluorescence that is emitted; a second step of mixing the photosynthetic sample with a standard sample, in which biological growth inhibition factors are not present, to prepare a standard measurement solution, letting the standard measurement solution stand, and then after illuminating light onto the standard measurement solution for a predetermined illumination time, measuring the light amount of the delayed fluorescence that is emitted; and a third step of computing assay values based on the light amounts of delayed fluorescence, respectively measured in the first step and the second step, and determining a comparison value of the assay